By BullScreen Editorial Team 
Indian pharmaceutical stocks surged on Tuesday after reports indicated that the US Food and Drug Administration (US FDA) has approached Indian drugmakers to help address a critical cancer drug shortage in the United States.
Shares of Cipla, Alkem Laboratories, and Zydus Lifesciences gained up to 2.4% in intraday trade, while broader sector players like Piramal Pharma and Gland Pharma also posted strong gains.
The rally followed reports that the US FDA reached out to the Indian Drug Manufacturers’ Association (IDMA) to identify manufacturers capable of supplying ifosfamide, a key chemotherapy drug used in treating testicular, bladder, and lung cancer. The move comes as the US faces a prolonged supply disruption after manufacturing issues at Baxter International, one of the largest suppliers of the drug.
The Nifty Pharma index jumped over 2% to 25,294.50 after the opening bell and was still trading 1.7% higher at 25,184 by mid-session, reflecting strong investor confidence. In comparison, the benchmark NIFTY 50 has fallen 7.7% year-to-date, while Nifty Pharma has gained over 11% in 2026.
Market participants see the development as a major export opportunity for Indian drugmakers, especially as the US FDA is reportedly willing to source from non-FDA-approved facilities during the shortage.
Adding to the positive outlook, the Indian rupee has weakened nearly 1% against the US dollar over the past month, improving export margins for pharma companies. Analysts believe any bulk supply contracts from the US could strengthen revenue visibility and further support valuations across India’s pharmaceutical sector.